EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSPKIG00000013458
Gene Symbol: CACNA1B
1 Cross references
218 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSPKIG00000024524
Gene Symbol: CACNA1D
2 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSPKIG00000000974
Gene Symbol: CACNA1E
1 Cross references
215 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSPKIG00000007646
Gene Symbol: CACNA1E
3 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSPKIG00000021560
Gene Symbol: CACNA1G
1 Cross references
196 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSPKIG00000017681
Gene Symbol: CACNA1H
1 Cross references
75 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSPKIG00000013659
Gene Symbol: CACNA1H
2 Cross references
205 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSPKIG00000013531
Gene Symbol: CACNA1I
2 Cross references
262 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSPKIG00000003593
Gene Symbol: CACNA1I
2 Cross references
262 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSPKIG00000016456
Gene Symbol: CNR1
4 Cross references
134 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSPKIG00000017908
Gene Symbol: CNR1
3 Cross references
150 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSPKIG00000000635
Gene Symbol: CNR2
1 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).